Suchergebnisse - "Luo, Peng-Hui"

PubPharm (27)

1

Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Luo, P. | Mo, D. | Wang, H. | +2

2

Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases

enthalten in: JAMA oncology | 2023

von Mo, D. | Luo, P. | Huang, J.

CommentOn: JAMA Oncol. 2023 Feb 1;9(2):197-205. - PMID 36454580

3

Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma

enthalten in: The Lancet. Oncology | 2023

von Mo, D. | Huang, J. | Luo, P. | +2

CommentOn: Lancet Oncol. 2023 Mar;24(3):252-261. - PMID 36858722

4

Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Huang, S. | Luo, P. | Wang, H. | +2

CommentOn: J Clin Oncol. 2023 Mar 10;41(8):1600-1609. - PMID 36413710

5

Low-Dose Immunotherapy Plus Triple Metronomic Chemotherapy for Head and Neck Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Mo, D. | Huang, J. | Luo, P.

CommentOn: J Clin Oncol. 2023 Jan 10;41(2):222-232. - PMID 36265101

6

Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma

enthalten in: The Lancet. Oncology | 2023

von Mo, D. | Huang, J. | Luo, P. | +2

CommentOn: Lancet Oncol. 2022 Nov;23(11):1378-1388. - PMID 36265502

7

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma : a systematic review and meta-analysis

enthalten in: Frontiers in immunology | 2023

von Feng, Y. | Xie, G. | Xiao, L. | +4

8

PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma

enthalten in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | 2023

von Mo, D. | Huang, J. | Luo, P. | +3

9

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer

enthalten in: Experimental and therapeutic medicine | 2022

von Mo, D. | Liang, Z. | Chen, L. | +3

10

Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers : A meta-analysis of randomized controlled trials

enthalten in: Medicine | 2022

von Mo, D. | Huang, J. | Luo, P. | +2